[Does the therapy with indomethacin interfere with growth in Bartter's syndrome in childhood?].
The authors describe a new-born form of Bartter's syndrome treated for about 6 years with Indomethacin in a quantity of 2 mg/Kg/die except short periods, during which it was given triamterene in a quantity of 2 mg/Kg/die. While with the first medicine the growth of height has had an average increase of about 9 cm a year, with the second one there hasn't been any result neither on growth nor on the rest of symptomatology. The A.A. on the base of recent experimental data think that the deficiency of height could be due to a scanty affinity of peripherical receptors and SmC, that could be removed from the provision of Indomethacin.
Di Pietro
A
A
28a Divisione di Pediatria Ospedale A. Cardarelli di Napoli, Italia.
Proverbio
M R
MR
Tommaselli
A P
AP
Pescatore
L
L
Chianese
F
F
Coletta
S
S
Race
G
G
Coletta
A
A
D001477:Bartter Syndrome / Q000188:drug therapy*; D002675:Child, Preschool; D005260:Female; D006128:Growth / Q000187:drug effects*; D006801:Humans; D007213:Indomethacin / Q000009:adverse effects* / Q000627:therapeutic use
D007213:Indomethacin
La terapia con indometacina interferisce con l'accrescimento nella sindrome di Bartter dell'infanzia?